Every 8-K that Danaher Corporation (DHR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DHR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DHR filings page.
Danaher Corporation is implementing a planned leadership transition, appointing Julie Sawyer Montgomery as President and Chief Executive Officer and a director effective October 1, 2026, while current CEO Rainer M. Blair becomes Senior Advisor through December 31, 2026 and a consultant through March 31, 2027.
Montgomery’s CEO compensation includes an offer letter and a special Long-Term Growth Award of time-vesting non-qualified stock options with a target value of $20,000,000, relocation benefits, various perquisites and defined severance protections equal to 12 months of base salary plus specified annual incentive components upon certain terminations. Blair’s transition letter maintains his base salary during the advisory period, provides consulting fees thereafter, and grants severance on separation equal to one year of salary, a target annual cash incentive and a 12‑month COBRA subsidy, subject to releases and existing restrictive covenants.
The board also approved long-term equity awards for other senior leaders, including a $12,500,000 option award to CFO Matthew Gugino, RSUs valued at $8,000,000 and $2,625,000 for two additional named executives, and for founders Steven and Mitchell Rales options on 1,000,000 shares and RSUs on 500,000 shares each with multi‑year vesting and 10‑year option terms. Danaher reiterates its previously communicated third‑quarter and full‑year 2026 guidance and plans to exclude stock‑based compensation from this Long-Term Growth Program when calculating Adjusted Diluted Net Earnings Per Share.
Danaher reported second quarter 2026 results from continuing operations with sales of $6.3 billion, up 5.5% year-over-year. Non-GAAP core revenue grew 3.0% and 4.5% excluding respiratory testing. Net earnings were $870 million, or $1.23 per diluted share, up 60% year-over-year. Adjusted diluted EPS (non-GAAP) rose 8.0% to $1.94 after excluding amortization of acquisition-related intangible assets, Masimo-related acquisition items and other adjustments detailed in the reconciliation. Management highlighted particularly strong performance in Life Sciences and mid-teens bioprocessing order growth despite project-timing headwinds.
Operating cash flow was $1.5 billion and free cash flow $1.3 billion, both higher than the prior year and exceeding net earnings. For third quarter 2026, Danaher anticipates non-GAAP core revenue growth of 2.0%–3.0%; for full year 2026 it expects 3.0%–4.0% growth and raised its adjusted diluted EPS guidance to $8.45–$8.60 from $8.35–$8.55. The company completed its Masimo acquisition earlier than anticipated and, through Leica Biosystems, plans to acquire StatLab, a histology products business with approximately $250 million of 2025 revenue that is expected to grow at a high-single-digit core rate and be accretive to adjusted EPS in the first full year after a targeted 2026 close.
Danaher Corporation has created new long-term debt through a private placement of multiple Swiss franc–denominated senior notes issued by wholly owned subsidiary DH Masi Finance Inc. and guaranteed by Danaher. The company sold CHF 119,500,000 of 1.65% Series A Notes due June 3, 2031 and CHF 137,410,000 of 1.88% Series B Notes due June 3, 2033, alongside larger tranches maturing between 2036 and 2056 at fixed interest rates ranging from 2.10% to 2.51% per year. Interest is payable semi-annually on June 3 and December 3, starting December 3, 2026. Net proceeds are expected to be used for general corporate purposes, including working capital, acquisitions and share repurchases.
Danaher Corporation reported results from its May 5, 2026 annual shareholder meeting. Shareholders approved an Amended and Restated Omnibus Incentive Plan that increases the plan’s share reserve by 20 million shares of common stock and extends its term to May 5, 2036.
All eleven director nominees were elected with strong majorities, and shareholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. Shareholders also approved, on an advisory basis, the company’s named executive officer compensation and formally approved the incentive plan itself.
Danaher Corporation completed a major euro-denominated debt offering to help finance its proposed acquisition of Masimo Corporation. The company issued €500 million of Floating Rate Senior Notes due 2028, €750 million of 3.250% Senior Notes due 2030, €750 million of 3.625% Senior Notes due 2034 and €1.0 billion of 4.000% Senior Notes due 2038.
Danaher received net proceeds of approximately €2.98 billion, which it plans to use primarily to pay a portion of the cash consideration and related costs for the Masimo acquisition, with any remainder available for general corporate purposes. The fixed-rate notes include a special mandatory redemption at 101% of principal plus interest if the Masimo deal is not completed under the merger agreement timeline, and investors also receive a 101% change-of-control repurchase right. The notes are unsecured senior obligations and include covenants limiting certain liens, sale-leasebacks and major structural transactions.
Danaher Corporation reported solid first quarter 2026 results driven by earnings growth and strong cash generation. Revenue from continuing operations rose 3.5% year-over-year to $6.0 billion, while non-GAAP core revenue increased 0.5%.
Net earnings were $1.0 billion, or $1.45 per diluted share, and non-GAAP adjusted diluted net earnings per share grew 9.5% to $2.06. Operating cash flow reached $1.3 billion and non-GAAP free cash flow was $1.1 billion, underscoring strong cash conversion.
Management highlighted a steady recovery with strength in Bioprocessing and Life Sciences, partially offset by a lighter-than-typical respiratory season at Cepheid. Danaher also announced its intention to acquire Masimo Corporation and raised full-year 2026 adjusted diluted EPS guidance to a range of $8.35 to $8.55.
Danaher Corporation entered into a new $5.0 billion 364-day revolving credit facility with Bank of America, N.A. as administrative agent and a syndicate of lenders. The facility expires on April 15, 2027 and can be converted at that date into term loans maturing one year later upon payment of a 0.50% fee on outstanding loans and satisfaction of conditions.
Borrowings bear variable interest, with Term SOFR loans priced at Term SOFR plus 58.5–108.5 basis points and Base Rate loans priced using a base formula plus a margin of 0–8.5 basis points, in each case depending on Danaher’s long‑term debt credit rating. Danaher also pays a 4.0 basis point annual facility fee on total commitments. The unsecured facility includes a covenant requiring a Consolidated Leverage Ratio of 0.65 to 1.00 or less and customary restrictions and events of default.
Danaher intends to use the facility to provide liquidity support for its U.S. dollar‑denominated commercial paper program and for general corporate purposes.
Danaher Corporation has agreed to acquire Masimo Corporation, a specialty diagnostics and patient monitoring company, in an all-cash deal. Danaher will pay $180 per Masimo share, implying a total enterprise value of about $9.9 billion including assumed debt and net of acquired cash.
The price represents roughly an 18x multiple of Masimo’s estimated 2027 EBITDA, or about 15x when including the full benefit of expected annual synergies. Masimo is expected to generate more than $530 million of EBITDA in 2027, with over $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year after closing.
Danaher expects the deal to add $0.15–$0.20 to adjusted diluted EPS in the first full year and about $0.70 by the fifth year. Masimo will operate as a standalone business within Danaher’s Diagnostics segment. The transaction is anticipated to close in the second half of 2026, funded with cash on hand and new debt, and remains subject to Masimo stockholder approval and customary regulatory clearances, including U.S. and non-U.S. antitrust and foreign investment reviews.
Danaher Corporation reported that director Jessica L. Mega has retired from its Board of Directors effective February 5, 2026. She stepped down because of commitments related to her other professional obligations.
The company stated that Dr. Mega’s decision was not due to any disagreement with Danaher regarding its operations, policies, or practices, indicating an orderly and amicable board transition.
Danaher Corporation furnished a current report to share its latest financial performance. On January 28, 2026, the company issued a press release detailing results for the year ended December 31, 2025, including fourth quarter performance, and attached this release as Exhibit 99.1.
The information was furnished under Item 2.02 and is expressly stated as not being deemed “filed” for liability purposes or automatically incorporated into other securities law filings, unless specifically referenced in a future document.
Danaher Corporation is providing an early look at its financial performance, sharing estimated results for the fourth quarter of 2025 and for full-year 2025. On January 12, 2026, the company issued a press release and presentation slides in connection with a public webcast at the J.P. Morgan Healthcare Conference on January 13, 2026. These materials, furnished under a current report, outline management’s view of recent performance and are incorporated by reference as exhibits, but are expressly designated as furnished rather than filed under securities law.
Danaher (DHR) announced a planned Board change. Director John T. Schwieters will not stand for reelection at the 2026 annual meeting and will retire at that time. The company stated his decision was not due to any disagreement on operations, policies, or practices.
Following his retirement, the Board size will be reduced from thirteen to twelve members. This is a governance update with no operational or financial changes disclosed.
Danaher Corporation furnished an 8‑K announcing its third‑quarter results. On October 21, 2025, the company issued a press release for the quarter ended September 26, 2025, attached as Exhibit 99.1 and incorporated by reference. The information is furnished under Item 2.02 and is expressly stated as not deemed “filed” under Section 18 of the Exchange Act.
Danaher Corporation reported that its Board of Directors amended and restated the company’s By-laws effective September 9, 2025. The changes update the advance notice rules and related procedures that shareholders must follow to propose business or nominate directors at shareholder meetings, along with other routine, non-substantive revisions.
The Board also approved a new share repurchase program authorizing the company to buy back up to 35 million shares of its common stock. Repurchases may occur over time in open-market purchases, privately negotiated deals, or other methods, including trading plans under Rule 10b5-1. This authorization is in addition to existing repurchase authorizations, has no expiration date, and will remain in effect until suspended or terminated by the company.